Clinical trials: Deglutition Disorder
Gastroesophageal Reflux Disease
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after…
- Trial name
- NCT05660122
- Testing
- Fexuprazan Hydrochloride
- Where
- South Korea
- Volunteers
- 2,852 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastro Esophageal Reflux
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
This is a post-market, multi-center, double-blind, placebo-controlled, randomized, cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD.
- Trial name
- NCT04202692
- Testing
- Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- SOFAR S.p.A.
Gastroesophageal Reflux
Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France
The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management
- Trial name
- NCT00681837
- Where
- 25 sites in China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
GERD
EndoStim Patient Registry
To provide a research tool enabling physicians to monitor long term clinical outcomes for patients undergoing gastroesophageal reflux disease (GERD) treatment with EndoStim LES Stimulation System.
- Trial name
- RESTORE (NCT02441400)
- Testing
- EndoStim LES Stimulation System
- Where
- 30 sites in Argentina, Austria and 5 more
- Volunteers
- 350 people
- Sponsor
- EndoStim Inc.
Amyotrophic Lateral Sclerosis
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
- Trial name
- ROSF (NCT03679975)
- Testing
- Riluzole Oral Soluble film (ROSF) 50 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Aquestive Therapeutics
Gastroesophageal Reflux Disease, Hiatal Hernia
Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD)
The study objective is to evaluate the relative merits, safety and effectiveness of transoral incisionless fundoplication (TIF) in proton pump inhibitor (PPI) dependent GERD patients compared with sham procedure.
- Trial name
- NCT01110811
- Testing
- Transoral Incisionless Fundoplication (TIF)
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 60 people
- Sponsor
- EndoGastric Solutions
Gastroesophageal Reflux Disease
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
To investigate the safety of C13-CAC and the relationship among C13-CAC breath test, gastric pH, and the improvement of symptoms by switching PPI in PPI resistant GERD patients
- Trial name
- NCT03284177
- Testing
- Calcium (13C)Carbonate, Gastric acid inhibitors, Gastric pH monitoring
- Where
- 13 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
GERD
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
- Trial name
- MAESTRO (NCT00444275)
- Testing
- esomeprazole (Nexium®), Xolaam®
- Where
- France
- Volunteers
- 3,029 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuest™ questionnaire…
- Trial name
- NCT00312806
- Testing
- Pantoprazole
- Where
- 186 sites in Argentina, Australia and 20 more
- Volunteers
- 2,000 people
- Sponsor
- Takeda
Gastroesophageal Reflux
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
- Trial name
- NCT05343364
- Testing
- Vonoprazan
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Healthy Volunteers
Single-dose and Multiple-dose X842 Phase 1 Study
The purpose of this study is to evaluate the safety and tolerability of X842 after administration of single and multiple doses in healthy subjects
- Trial name
- NCT04293965
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Food Effect
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
GERD
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use
The purpose of the study is to examine the impact of augmented, high-quality physician-coordinated care executed via an electronic health record (EHR)-based intervention on quality of care for gastroesophageal reflux disease…
- Trial name
- NCT00691171
- Volunteers
- 5,234 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.
- Trial name
- NCT04622358
- Testing
- AD-214-02, Rabeprazole
- Where
- South Korea
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Laryngeal Disease, Laryngeal Tumor
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will…
- Conditions
- Laryngeal Disease, Laryngeal Tumor, Laryngopharyngeal Reflux
- Trial name
- NCT03214835
- Testing
- Endo CDx Brush biopsy
- Sponsor
- CDx Diagnostics
Gastro Esophageal Reflux
Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease
The aim of this study is to investigate whether a 3-week treatment with an oral melt in mouth medical device, made up with hyaluronic acid, chondroitin sulphate and magnesium trisilicate, can lead to a reduction of…
- Trial name
- NCT03883074
- Testing
- hyaluronic acid with chondroitin + sulphate + magnesium trisilicate
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- SOFAR S.p.A.
Functional Gastrointestinal Disorders
Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an…
- Trial name
- NCT06488274
- Testing
- New infant formula
- Where
- 4 sites in France
- Volunteers
- 139 people
- Sponsor
- United Pharmaceuticals
Gastroesophageal Reflux Disease
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
- Trial name
- NCT00220818
- Testing
- Lansoprazole
- Volunteers
- 24 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561090
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 99 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.